TrialHeart (British Cardiac Society)2021

Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease.

Gilles R Dagenais et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.